Date: 26 December 2021
Your Name: Weize Lv
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All Coll	Time frame: Since the initial	planning of the work
1	All support for the present	_√_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	✓ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ ✓ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

ate: 26 December 2021
our Name: Xiaofeng Pei
lanuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
on-small-cell lung cancer
lanuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All Coll	Time frame: Since the initial	planning of the work
1	All support for the present	_√_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	✓ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ ✓ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Date: 26 December 2021
Your Name: Wenhua Zhao
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All Coll	Time frame: Since the initial	planning of the work
1	All support for the present	_√_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	✓ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ ✓ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All Coll	Time frame: Since the initial	planning of the work
1	All support for the present	_√_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	✓ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ ✓ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Date: 26 December 2021
Your Name: Yajun Wei
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All Coll	Time frame: Since the initial	planning of the work
1	All support for the present	_√_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	✓ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ ✓ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Date: 26 December 2021
Your Name: Ting Li
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All Coll	Time frame: Since the initial	planning of the work
1	All support for the present	_√_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	✓ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ ✓ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Date: 26 December 2021
Your Name: Hongyu Zhang
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ ✓ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_✓_None	
3	Royalties or licenses	✓ _None	
4	Consulting fees	✓_None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	✓ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ ✓ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Date: 26 December 2021
Your Name: Zhong Lin
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All Coll	Time frame: Since the initial	planning of the work
1	All support for the present	_ √ _None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	/ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ ✓ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Date: 26 December 2021
Your Name: Yuichi Saito
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All augus out four the process	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	_ √ _None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	/ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ ✓ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Your Name: Jae Jun Kim Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All Coll	Time frame: Since the initial	planning of the work
1	All support for the present	_√_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	/ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ √ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Date: 26 December 2021
Your Name: Zibin Liang
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All augus out four the process	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	_ √ _None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	/ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ √ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Date: 26 December 2021
Your Name: Beilong Zhong
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All augus out four the process	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	_ √ _None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ √ _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ √ _None	
4	Consulting fees	_ √ _None	

5 Payment or honoraria for	✓ None			
5 Payment or honoraria for	/ None			
•	_v _None			
lectures, presentations,				
speakers bureaus,				
manuscript writing or				
educational events				
6 Payment for expert	/ _None			
testimony				
7 Compart for attacking				
7 Support for attending meetings and/or travel	_ √ _None			
8 Patents planned, issued or	_ √ _None			
pending				
9 Participation on a Data	_ √ _None			
Safety Monitoring Board or				
Advisory Board				
10 Leadership or fiduciary role	_ √ _None			
in other board, society,				
committee or advocacy				
group, paid or unpaid 11 Stock or stock options	/ Name			
11 Stock of Stock options	_ √ _None			
12 Receipt of equipment,	✓ None			
materials, drugs, medical	INOILE			
writing, gifts or other				
services				
13 Other financial or non-	_ √ _None			
financial interests				
Please summarize the above conflict of interest in the following box:				

None.			

Date: 26 December 2021
Your Name: Zhihui Wang
Manuscript Title: Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced
non-small-cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
1	Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	_ √ _None							
	No time limit for this item.								
		Time frame: past	36 months						
2	Grants or contracts from	_ √ _None							
	any entity (if not indicated								
	in item #1 above).								
3	Royalties or licenses	_ √ _None							
4	Consulting fees	_ √ _None							

5 Payment or honoraria for	✓ None					
5 Payment or honoraria for	√ None					
The state of the s	_ V _IVOIIC					
lectures, presentations,						
speakers bureaus,						
manuscript writing or						
educational events						
6 Payment for expert	✓_None					
testimony						
7 Compart for attacking						
7 Support for attending meetings and/or travel	_ ✓ _None					
8 Patents planned, issued or	_√_None					
pending						
9 Participation on a Data	_√_None					
Safety Monitoring Board or						
Advisory Board						
10 Leadership or fiduciary role	_√_None					
in other board, society,						
committee or advocacy						
group, paid or unpaid 11 Stock or stock options	/ Name					
11 Stock of Stock options	✓_None					
12 Receipt of equipment,	✓ None					
materials, drugs, medical	INOILE					
writing, gifts or other						
services						
13 Other financial or non-	_√_None					
financial interests						
Please summarize the above conflict of interest in the following box:						

None.			